Abstract Library

#2084 A Comparison of Diagnostic and Management Pathways for Patients with Lung Neuroendocrine Tumors in ENETS Centres of Excellence vs Non-Accredited Centres in the UK: Results from the National Lung NET Pathway Project (‘LEAP’)

Introduction: The ENETS network of accredited NET Centres of Excellence (CoE) across Europe was established to standardise and improve NET management.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Talbot D

Authors: Talbot D, Ferguson S, Mansoor W,

Keywords: Treatment pathways, Lung NET, Centre of Excellence, ENETS, Diagnostics,

#2046 Histopathological Revision for Gastroenteropancreatic Neuroendocrine Neoplasms in Expert Centers: Does It Make the Difference?

Introduction: A proportion of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) referred to NEN expert centers need a histopathological revision.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Merola E

Authors: Merola E, Zandee W, de Mestier L, Klümpen H, Geboes K,

Keywords: neuroendocrine, NET referral centers, histopathological revision, patient management,

#1610 Clinical Significance of Incidental Detection of Appendicular Neuroendocrine Tumours in Sri Lanka

Introduction: Neuroendocrine tumours are known to occur in the appendix and mostly detected incidentally following appendicectomies for acute appendicitis. Most of them have a benign behavior and no clinically significant biological activity is found. However, the correct recognition of the pathology is of paramount importance as it may need a separate evaluation and management.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lal D

Authors: Lal D,

Keywords: Appendicular NET,

#1529 Somatostatin Receptor PET/CT with Radiolabelled Antagonist Is Twice as Effective as the Agonist for Detecting Liver Metastases: Results of a Phase 1/2 Study Comparing 68Ga-OPS202 with 68Ga-DOTATOC PET/CT in Gastroenteropancreatic NET Patients

Introduction: 68Ga-DOTATOC PET/CT is a reference method for imaging somatostatin receptor (sstr) expressing neuroendocrine tumors (NET). Presence and extent of liver metastases impact on patient management and prognosis.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Nicolas G

Authors: Nicolas G, Schreiter N, Kaul F, Uiters J, Mena R,

Keywords: Radiolabelled somatostatin antagonist, PET, GEP-NET,

#1525 Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education

Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Davies P,

Keywords: everolimus, patient education, side effects,